Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.

Deltenre, Pierre; Moreno, Christophe; Trépo, Eric

Deltenre, Pierre; Moreno, Christophe; Trépo, Eric.

Deltenre P; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Department of Gastroenterology and Hepatology, Clinique St Luc, Bouge, Belgium. Electronic address: pierre.deltenre01@gmail.com.
Moreno C; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.
Trépo E; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.

J Hepatol ; 75(4): 989-990, 2021 10.

Article in English | MEDLINE | ID: covidwho-1141978

Subject(s)

COVID-19; Ketamine; Humans; Ketamine/adverse effects; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Ketamine Limits: Humans Language: English Journal: J Hepatol Journal subject: Gastroenterology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google